Moderna: More than just COVID-19
Reading Time: 3 minutes
Moderna has made a name for itself with its mRNA vaccine against COVID-19, but the company is already working on a broader range of innovative therapies. Personalized cancer vaccines developed in collaboration with Merck are particularly in focus, holding the potential to fundamentally change oncology. In addition, Moderna is advancing research on mRNA-based vaccines against influenza and other infectious diseases. While revenues have declined after the peak of the pandemic, the pipeline remains promising, and initial results from ongoing studies...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
